Relmada Therapeutics, Inc. (RLMD) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Coral Gables, FL, 미국. 현재 CEO는 Sergio Traversa.
RLMD 을(를) 보유 IPO 날짜 2014-06-20, 17 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $527.27M.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
